In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H discuss HIMS' recent performance and the unveiling of their upcoming minute-long Super Bowl ad. The discussion delves into the strategic rationale behind this move, its potential to create strong brand awareness, and its alignment with the broader goal of establishing a 'brand moat.' The trio then addresses the record-high short interest in HIMS, now exceeding 30%, and analyzes the dynamics that could lead to a short squeeze. The episode concludes with speculation about a potential new product—testosterone therapy—and its implications for HIMS' expanding multi-product portfolio.

00:44 Super Bowl Ad

01:04 Brand Awareness and Marketing Strategy

08:06 Political Messaging in Advertising

19:10 Record High Short Interest

26:26 Understanding Short Squeeze Potential

29:04 Analyzing Short Interest and Market Perception

30:50 Historical Context of Shorted Stocks

34:41 GameStop Comparison and Stock Value Fundamentals

39:38 Potential New Product: Testosterone

47:22 Conclusion and Final Thoughts

NOTE: Analysis and opinions expressed by Jack are his and his alone, and are not to be interpreted as a reflection of opinions by his current or former employers.

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H are joined by a special guest, Jack, a former sell-side analyst. Jack provides a comprehensive analysis of the Hims & Hers business, rooted in his years of following the company since 2022. The discussion kicks off with an overview of the financial industry, contrasting the roles of sell-side and buy-side analysts. Jack elaborates on his interest in following HIMS, emphasizing the company's successful transition from a patient-centric to a consumer-centric healthcare provider. The episode highlights a recent Bank of America report predicting a revenue shortfall for HIMS, exploring credit card data intricacies and deferred revenue impacts. Finally, the conversation delves into HIMS' long-term prospects, potential regulatory hurdles, international viability, and their unique market position.

00:00 Introduction

00:42 Understanding the Sell Side vs. Buy Side

02:17 Jack's Interest in HIMS

03:46 Bank of America Report Analysis

05:42 Deferred Revenue and Credit Card Data

11:40 Impact of Amazon on HIMS

18:32 Consumer vs. Patient Behavior

22:07 Cash Pay Option in Healthcare

26:22 HIMS' Long-Term Vision and International Expansion

31:35 Debating the Future of Diabetes Care

32:41 Challenges in High Acuity Care

34:04 Teladoc and Livongo: A Case Study

36:07 Impact of COVID on Digital Health

40:21 Consumer vs. Patient Psychology

47:01 The Future of Weight Loss and Diabetes Treatment

52:08 2025 Predictions and Key Indicators

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H are joined by Bayside, a professional lobbyist in Washington D.C., to discuss the upcoming Trump administration and its potential impact on Hims, particularly concerning the semaglutide shortage. Bayside provides a detailed analysis of the semaglutide and tirzepatide shortages, FDA decisions, and political landscape affecting HIMS investors. The discussion expands to consider the potential influence of Elon Musk and Trump on healthcare policy, Greenland acquisition implications, and the roles of RFK and Marty Makary in shaping future healthcare regulations. Dr. H offers insights into the medical necessity of compounded medications and telehealth implications.

00:00 Introduction

01:05 Semaglutide Shortage Analysis

02:48 FDA Decision Timeline

06:44 Impact of New Administration

10:34 HIMS Sales Strategy Post-Shortage

14:29 Legal and Medical Perspectives

28:57 Custom Dosage and Medical Necessity

29:46 Corporate Practice of Medicine

30:28 Patent System and Compounding Controversy

31:30 Chevron Doctrine and Legal Battles

32:08 Impact on HIMS Stock and Lawsuits

34:59 Future of Compounding and Revenue

36:58 Elon Musk, Trump, and GLP-1 Pricing

42:02 Greenland and Geopolitical Leverage

46:46 RFK and Marty McCary's Impact on Healthcare

57:46 Conclusion and Future Topics

Full access to our HIMS Data Dashboard + research library is $10/mo ($100/yr). Join 1,400 other HIMS investors today!

In episode 17 of Hims House, Jonathan Stern, Louis Stevens, and Dr. H reflect on the significant milestones and performance of Hims & Hers in 2024, marking it as a watershed year for the company. They discuss the company's financial growth, product launches, strategic hires, and customer base expansion. The trio also dissects the challenges faced, including legal battles and market skepticism. The conversation highlights Hims' expansion into weight loss treatments, branding strategies, and the implications of free cash flow and customer acquisition costs. Looking ahead, they share their predictions for 2025, focusing on growth opportunities and potential stock performance.

00:00 New Year Greetings

00:29 2024 Year in Review: Key Highlights

00:51 HIMS Company History and Growth

02:19 Financial Performance and Market Dynamics

07:21 Marketing and Brand Recognition

08:18 New Products and Strategic Hires

11:02 Surprises and Strategic Decisions

15:24 Stock Market Performance and Sentiment

20:16 Biggest Wins of 2024

24:49 Subscriber Growth and Acquisitions

29:21 Looking Ahead to 2025

34:03 Predictions and Final Thoughts

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H are joined by a special guest, Bayside, a professional lobbyist who works in Washington D.C. They discuss the recent FDA announcement about the tirzepatide shortage resolution and its implications on HIMS. Bayside shares insights from his 12-page research report, which accurately predicted this outcome, and provides a detailed analysis of FDA politics, the pharmaceutical industry, and future expectations for GLP-1 compounds like semaglutide. The episode also explores potential partnerships, legal challenges, and the role of personalized medicine in the context of compounding.

00:00 Introduction

00:31 FDA Announcement and Market Reaction

00:53 Bayside's Research and Predictions

04:27 Political and Legal Implications

08:15 Semaglutide Shortage and Market Impact

19:23 Court Filings and Hims Supply Tracker

20:43 Reactions and Future Outlook

21:22 FDA Regulations and Discretion

22:35 Elon Musk's Influence and Motivations

23:31 Compounding and Personalized Medicine

26:01 Legal and Medical Perspectives on Dosage Variances

31:01 Hims and the Pharmaceutical Industry

36:25 Future of GLP-1 Drugs and Market Dynamics

41:35 Speculations and Future Partnerships

In episode 15 of Hims House, Jonathan Stern, Louis Stevens, and Dr. H discuss recent news about Meta restricting data access for healthcare companies like Hims and the implications for Hims’ marketing strategies. They examine the parallels between Meta's past challenges with Apple's privacy policies and how Hims might navigate similar issues, ultimately predicting that Hims’ vertically integrated platform will help it thrive. The episode also covers new partnerships in the telehealth industry, such as Ro partnering with pharmaceutical giant Lilly, and debates the American Diabetes Association's stance against compounded GLP-1 drugs, highlighting concerns around safety and efficacy while affirming Hims’ robust approach to patient care.

00:00 Introduction

01:46 Why Meta’s Data Restriction Might Be Bullish

05:58 Meta's Transition from Bearish to Bullish

14:35 Ro and Lilly Partnership Announcement

27:02 American Diabetes Association Stance on Compounded GLP-1s

44:33 Primary Care and Telemedicine Expertise

Subscribe to Hims House!

Website: himshouse.substack.com

Twitter/X: x.com/himshouse

Discord: discord.gg/tJqGgVhkEt

Follow us on Twitter/X:

Jonathan Stern - x.com/jonathanrstern

Louis Stevens - x.com/LA_stevens_

Dr. H - x.com/stayathomedoc

In Episode 14 of Hims House, host Jonathan Stern is joined by Louis Stevens and Dr. H to discuss the FDA's delayed decision on terzepatide shortages, its implications for Hims, and how it may reflect on semaglutide. They dive into the importance of anchoring to the long-term vision of Hims amid market volatility and debate the FDA’s growing acknowledgment of the medication shortage. The team also explores the newly launched meal replacement bars and shakes by Hims and their potential impact on the business. They further discuss the market reactions, the diverse weight loss product range, and the integral understanding needed for sustainable growth in the telehealth and wellness space.

00:00 Introduction and Episode Overview

00:30 FDA Decision on Terzapatide Shortage

01:04 Impact on Hims and Market Reactions

01:35 Review of FDA's Actions and Industry Reactions

05:31 Discussion on Compounded Medications

11:34 Remembering the Long-Term Thesis for Hims

28:58 New Product Launch: Meal Replacement Bars and Shakes

In Episode 13 of Hims House, Jonathan Stern, Louis Stevens, and Dr. H discuss the implications of Amazon's telemedicine announcements on Hims & Hers. They examine Amazon's pricing, offerings, and potential market overlap with Hims, while exploring whether this presents a serious threat or is overhyped by speculative narratives on platforms like Twitter. The conversation transitions to Hims’s strategic positioning, emphasizing customization, trust, and long-term customer relationships as competitive advantages. The team also delves into the regulatory uncertainty surrounding GLP-1 medications and how Hims is positioning itself with alternative treatments to address future challenges.

00:00 Welcome and Introduction

00:14 Amazon's New Pricing Announcement

01:31 Impact on Hims and Market Reactions

03:41 Patient Preferences and Pricing

06:50 Bear Arguments in Response To the News

12:09 Amazon Not Doing Weight Loss

13:33 Historical Context of Market Competition

23:56 Customer Base Overlap Between Amazon Prime and Hims

35:57 GLP-1 Supply Tracker and Regulatory Challenges

46:21 Conclusion

Website: https://himshouse.substack.com

Twitter/X: @himshouse

Discord: https://discord.gg/tJqGgVhkEt

Jonathan Stern - @jonathanrstern

Louis Stevens - @LA_stevens_

Dr. H - @stayathomedoc

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H dive into Hims & Hers Health's Q3 earnings report. With a record-breaking number of subscribers now exceeding 2 million and significant financial metrics that outperformed estimates, the team dissects key data points and discusses the company's strategic direction. Topics include the rise of personalized solutions among subscribers, the impact of GLP-1 adoption, and the anticipated launch of liraglutide. The episode also touches on potential meal replacements, stock buybacks, financial health indicators, and the ongoing evolution of Hims' multi-product platform.

00:00 Introduction and Q3 Earnings Overview

00:22 Key Metrics and Achievements

01:25 High-Level Reactions and Insights

05:14 Analysis of GLP-1s and Liraglutide

09:05 Personalized Medicine Record Numbers

13:27 Financial Metrics and Shareholder Insights

18:06 North Star Metrics

23:09 Weight Loss Products and Market Impact

33:00 Speculations and Future Products

41:23 Final Thoughts

Website: https://himshouse.substack.com

Twitter/X: @himshouse

Discord: https://discord.gg/tJqGgVhkEt

Jonathan Stern - @jonathanrstern

Louis Stevens - @LA_stevens_

Dr. H - @stayathomedoc

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H provide a comprehensive preview of Hims' upcoming Q3 2024 earnings report. They discuss past earnings performance, market reactions, volatility, and expectations for future earnings. Key points include Hims' historical revenue growth, the impact of GLP-1 medications, vertical integrations, and forward-looking projections for the company. The discussion highlights the importance of customer acquisition costs, the value of the new 503B pharmacy, and the anticipation of new product launches. Additionally, the team provides insights into investor sentiment and potential stock price movements post-earnings report.

00:00 Introduction and Overview

00:18 Setting the Stage for Q3 Earnings

00:27 Historical Performance and Market Reactions

03:26 Q2 2024 Recap and Expectations

05:17 Insights from Dr. H on Telehealth and GLP-1

06:44 Hims' Revenue Guidance and Projections

10:47 Discussion on Business Growth and Sustainability

13:37 Product Announcements and Future Roadmap

25:08 503B Pharmacy Acquisition and Vertical Integration

30:13 Earnings Predictions and Stock Price Projections